ChemicalBook > Product Catalog >API >Respiratory Drugs >Asthma drugs >Montelukast sodium

Montelukast sodium

Montelukast sodium Suppliers list
Company Name: Capot Chemical Co.,Ltd.
Tel: +86 (0)571-855 867 18
Email: sales@capotchem.com
Products Intro: Product Name:Montelukast Soudium Tablets
CAS:151767-02-1
Purity:98%(Min.HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Email: info@tianfuchem.com
Products Intro: CAS:151767-02-1
Purity:99% Package:500G;1KG;5KG;25KG
Company Name: Shenzhen Sendi Biotechnology Co.Ltd.
Tel: 0755-23311925 18102838259
Email: Abel@chembj.com
Products Intro: Product Name:Montelukast sodium
CAS:151767-02-1
Purity:99% Package:12100/KG
Company Name: Dalian Richfortune Chemicals Co., Ltd
Tel: 86-411-84820922, 84821539
Email: sales@richfortunechem.com
Products Intro:
Company Name: Arromax Pharmatech Co., Ltd.  Gold
Tel:0512-62959601 ,15995748448 ;QQ2063939626
Email:meizhang.sales@arromax.com
Products Intro:Product Name:Montelukast sodiuM
CAS:151767-02-1
Purity:>99.5% Package:100g,500g,1kg及以上 Remarks:API
Montelukast sodium Basic information
Pharmacological effect Uses
Product Name:Montelukast sodium
Synonyms:singulair;MONTELUKAST NA;MONTELUKAST SODIUM;mk-476;2-[1-[[1-[3-[2-[(7-chloro-2-quinolyl)]vinyl]phenyl]-3-[2-(1-hydroxy-1-methyl-ethyl)phenyl]-propyl]sulfanylmethyl]cyclopropyl]acetic acid sodium salt;1-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic;MK-476, Singulair;Montelukast, Sodium Salt
CAS:151767-02-1
MF:C35H35ClNNaO3S
MW:608.17
EINECS:
Product Categories:Active Pharmaceutical Ingredients;APIs;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Isotope Labeled Compounds;Pharmaceutical intermediates;DIOXYLINE;Other APIs;Inhibitors
Mol File:151767-02-1.mol
Montelukast sodium Structure
Montelukast sodium Chemical Properties
storage temp. -20°C Freezer, Under Inert Atmosphere
solubility DMSO: ≥8mg/mL at 60°C
color white to tan
Merck 14,6258
Safety Information
Hazard Codes Xi
Risk Statements 63-41-62
Safety Statements 26
RTECS GZ0698000
MSDS Information
Montelukast sodium Usage And Synthesis
Pharmacological effectCysteinyl leukotrienes (LTC4, LTD4, LTE4) is a eicosane-type substance released by various kinds of cells including mast cells and eosinophils with strong inflammatory effect. These important asthma pre-inflammatory mediators can bind to the Cysteinyl leukotriene receptors (CysLT) identified in the human airways, resulting in a variety of airway responses including bronchoconstriction, mucus secretion, increased vascular permeability, and eosinophil accumulation.
Montelukast sodium is an orally active selective leukotriene receptor antagonist that can specifically inhibit the cysteinyl leukotriene receptor. It was successfully developed by the Merck Company (German) and had entered into market in Canada, Finland, and Mexican in 1997. It is suitable for the prevention and long-term treatment of adults and children asthma, including the prevention of daytime and nighttime asthma symptoms, the treatment of asthma patients who are aspirin-sensitive and prevention of exercise-induced bronchial contraction, it can also be used to relieve the seasonal allergic rhinitis symptoms of 15 year-old or over 15 year-old patients whose symptoms are invalid and intolerant to other treatment.
Montelukast is a selective leukotriene receptor antagonist and has been approved for the oral administration treatment of asthma and allergic rhinitis. It is also a potent oral preparation that can significantly improve the inflammatory indicators. Biological determination of biochemistry and pharmacology has showed that montelukast sodium has a high affinity and selectivity to the CysLT1 receptors (compared with other kinds of pharmacologically important airway receptors such as prostanoid, cholinergic and β-adrenergic receptors). Montelukast can effectively suppress the physiological effects caused by the binding between LTC4, LTD4 and LTE4 receptor and CysLT1 receptor without any receptor agonistic activity. There is the secondary type of cysteinyl leukotriene receptor (CysLT2) presented in the lungs cysteinyl leukotriene receptor but may be limited to the blood vessels. So far, researchers haven’t cloned two receptors so the situation of CysLT receptor is illustrated through binding assay and pharmacological analysis. It has been now thought that montelukast does not antagonize CysLT2 receptors.
The above information is edited by the chemicalbook of Dai Xiongfeng.
UsesIt can be applied to alleviate the symptoms caused by allergic rhinitis.
UsesA selective leukotriene D4-receptor antagonist. Used as an antiasthmatic
Usesantiinfective
UsesA potent and highly selective CysLT1 receptor antagonist, without demonstrated CysLT2 activity
Montelukast sodium Preparation Products And Raw materials
Tag:Montelukast sodium(151767-02-1) Related Product Information
Methyl salicylate Difluorochloromethane Montelukast PHENYL VALERATE MONTELUKAST Sodium sulfate Methyl Diclofenac sodium Sodium benzoate Kresoxim-methyl Sodium bicarbonate Tribenuron methyl Thiophanate-methyl Sodium chlorite Methyl bromide CHLOROPHOSPHONAZO III Sodium hydroxide Sodium chloride